Jupiter Life Line Hospitals Ltd Q3 FY25 Earnings Analysis
Published 6 Jul 2026 | Healthcare Services | Market Cap: ₹10.6K Cr
Price
₹318
Market Cap
₹10.6K Cr
P/E Ratio
55.6
How does Jupiter Life Line Hospitals Ltd rank in Healthcare Services?
Compare Jupiter Life Line Hospitals Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Jupiter Life Line Hospitals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹388 Cr, net profit ₹50 Cr.
Full financials →Earnings Summary
Revenue for Q3 FY25 stood at Rs. Jupiter Life Line Hospitals anticipates initial EBITDA losses for new hospitals in the first year, with breakeven expected by the second year and profitability by the third year. - Margin expansion levers include inflation-linked price hikes (Thane), occupancy growth (Pune), and case mix optimization (Indore) expected to continue for 1-1.5 years. - Occupancy rates are poised to improve, with current occupancy around 65-66%, and planned bed additions to manage demand. - ARPOB is increasing (Rs 61,750 in Q3 FY25 vs.
📊 Revenue & Sales Performance
- →Revenue for Q3 FY25 stood at Rs. 322 crores, a 17.7% YoY increase; 9-month revenue was Rs. 934.8 crores, up 19.5% YoY.
- →Volume increased from 651,500 to 727,500 in 9 months.
- →Occupancy improved to 66.7% from 63.2% YoY.
- →ARPOB (Average Revenue Per Occupied Bed) increased to Rs. 59,100 from Rs. 53,600 YoY.
- →Expansion via three new hospitals (Dombivli 500 beds by Q1 FY27, Pune 500 beds by 2028, Mira Road 300 beds by 2029) aims to increase bed capacity to ~2,500.
- →Industry norm suggests new hospitals will be EBITDA negative in year 1, breakeven in year 2, and positive in year 3.
- →Demand in catchment areas, such as Mira Bhayandar with 2-3 million underserved residents, can drive volume growth.
- →Margins expected to improve with occupancy growth, price hikes, and case-mix optimization, particularly in Pune and Indore.
📈 Profitability & Margins
- →Jupiter Life Line Hospitals anticipates initial EBITDA losses for new hospitals in the first year, with breakeven expected by the second year and profitability by the third year.
- →Margin expansion levers include inflation-linked price hikes (Thane), occupancy growth (Pune), and case mix optimization (Indore) expected to continue for 1-1.5 years.
- →Occupancy rates are poised to improve, with current occupancy around 65-66%, and planned bed additions to manage demand.
- →ARPOB is increasing (Rs 61,750 in Q3 FY25 vs. Rs 59,100 in 9 months FY25), supporting revenue growth.
- →The company projects growing internal accruals without immediate need for additional debt, supporting capital expenditure for new hospitals.
- →With three new hospitals planned by FY27-FY29, revenue and profits are expected to scale up steadily as these facilities stabilize and grow.
🏗️ Capital Expenditure Plans
- →Current CAPEX for FY25 (9 months) excluding recent land acquisition is around Rs. 100 crores, mainly for Dombivli and Indore projects.
- →Total planned CAPEX for three new hospitals (Dombivli, Pune 2 at Bibvewadi, Mira Road) is approximately Rs. 1,400 crores.
- →Land acquisition in Mira Road for around Rs. 75 crores, fully funded through internal accruals and equity reserves.
- →Mira Road hospital planned as a 300-bed full-service multi-specialty hospital with an estimated total CAPEX of Rs. 400 crores (including land).
- →Dombivli hospital expected operational by Q1 FY27 with staggered investment.
- →The company intends to fund these projects largely through existing cash reserves (Rs. 250+ crores), internal accruals, and cash flow without additional debt for now.
- →Possibility of future funding through debt or equity will be evaluated if new projects arise beyond these three hospitals.
💰 Fundraising & Capital Structure
📋 Order Book & Pipeline
- →Jupiter Life Line Hospitals has a pipeline of three new hospitals in addition to the existing three operational ones.
- →New hospitals planned:
- → - Dombivli: 500 beds, expected operational by Q1 FY27.
- → - Pune 2 (Bibvewadi): 500 beds, expected operational in calendar year 2028.
- → - Mira Road: 300 beds, expected operational in calendar year 2029.
- →Total bed capacity after new hospitals will be approximately 2,500 beds.
- →Estimated CAPEX for these three hospitals is around Rs. 1,400 crores.
- →Recent land acquisition in Mira Road was for Rs. 75 crores, part of the Rs. 400 crore estimated CAPEX for that hospital.
- →Funding for the CAPEX will come from current cash reserves, internal accruals, and no immediate additional debt is planned.
- →No formal EBITDA loss guidance, but first-year EBITDA expected negative and breakeven by the second year for new hospitals.
Key Metrics
Frequently Asked Questions
What were Jupiter Life Line Hospitals Ltd Q3 FY25 results?
Revenue for Q3 FY25 stood at Rs. Jupiter Life Line Hospitals anticipates initial EBITDA losses for new hospitals in the first year, with breakeven expected by the second year and profitability by the third year. - Margin expansion levers include inflation-linked price hikes (Thane), occupancy growth (Pune), and case mix optimization (Indore) expected to continue for 1-1.5 years. - Occupancy rates are poised to improve, with current occupancy around 65-66%, and planned bed additions to manage demand. - ARPOB is increasing (Rs 61,750 in Q3 FY25 vs.
What is Jupiter Life Line Hospitals Ltd share price analysis?
Jupiter Life Line Hospitals Ltd currently shows a neutral. The stock trades at a P/E of 55.6 with a market cap of ₹10,620 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jupiter Life Line Hospitals Ltd planning capital expenditure?
Current CAPEX for FY25 (9 months) excluding recent land acquisition is around Rs.
Keep Jupiter Life Line Hospitals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.